La Jolla Pharmaceutical Company – Catecholamine Resistant Hypotension (CRH)

Submitted By:
Published Date:
January 25, 2020

Access Program Information

The primary objective of the study is to provide access to LJPC-501 for distributive shock
patients who remain hypotensive despite receiving fluid and vasopressor therapy.

Rare Disease:
Lymphangioleiomyomatosis